COVID-19 Resource Center

COVID-19 Resource Center

Source:

Press Release

 

Disclosures: Bailey is president of the AMA.
May 04, 2021
1 min read
Save

AMA announces CPT codes for Novavax COVID-19 vaccine

Source:

Press Release

 

Disclosures: Bailey is president of the AMA.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The AMA announced that the CPT code set was updated to include codes for the COVID-19 vaccine developed by Novavax. The codes will be effective upon FDA approval or emergency use authorization, according to a press release.

The provisional codes were announced today so that health care systems can prepare their electronic systems in advance, the release said.

Source: Adobe Stock

Previously, the AMA announced CPT codes for the COVID-19 vaccines developed by AstraZeneca, Johnson & Johnson, Moderna and Pfizer-BioNTech before vaccine approval or emergency use authorization.

“Relying on multiple manufacturers to produce different COVID-19 vaccine products helps to avoid possible supply disruptions and supports the needed volume of doses,” Susan R. Bailey, MD, president of the AMA, said in the press release. “However, accurately correlating vaccinated patients with one of the available COVID-19 vaccines is critical for managing immunizations. This challenge is managed with unique CPT codes that clinically distinguish each COVID-19 vaccine and provide the needed informational precision to ensure optimal vaccine distribution and administration.”

The Novavax COVID-19 vaccine Category I CPT codes and long descriptors are:

  • 91304: “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use;”
  • 0041A: “immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose;” and
  • 0042A: “immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose.”